News Related to Autosomal Dominant Optic Atrophy

Related coverage linked through entity extraction aliases.

Orphan Drug Designation Drives Rare Disease Therapy Development Across Global Markets

Mar 15, 2026

Regulatory incentives for rare disease treatments, including market exclusivity and development subsidies, are spurring pharmaceutical innovation across the US, Europe, Japan, and Australia, with multiple companies advancing therapies for conditions affecting limited patient populations.

Stoke Therapeutics Reports Durable Dravet Data, Expects Phase 3 Enrollment Completion in Q2 2026

Feb 23, 2026

Stoke Therapeutics presented long-term Dravet syndrome data showing up to 80% seizure reductions sustained through three years, outlined its Phase 3 EMPEROR trial design targeting mid-2027 data, and disclosed first patient dosing in its ADOA program.